Sugi Predict

Sugi Predict / Compounds / SCHEMBL927495

SCHEMBL927495

SCHEMBL927495

Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3[n+]([O-])cc21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 18/20 0.78
▸ PIK3CA P42336 15/20 0.78
▸ PIK3CD O00329 7/20 0.78
▸ PIK3CG P48736 6/20 0.78
▸ PIK3CB P42338 5/20 0.78
▸ PRKDC P78527 3/20 0.78
▸ ATM Q13315 3/20 0.78
▸ PIK3C2A O00443 2/20 0.78
▸ PIK3C2B O00750 2/20 0.78
▸ ATR Q13535 2/20 0.78
▸ CHEK1 O14757 1/20 0.78
▸ ABCB11 O95342 1/20 0.78
▸ CSF1R P07333 1/20 0.78
▸ MET P08581 1/20 0.78
▸ PIK3R1 P27986 1/20 0.78
▸ LTK P29376 1/20 0.78
▸ CDK7 P50613 1/20 0.78
▸ NEK2 P51955 1/20 0.78
▸ JAK3 P52333 1/20 0.78
▸ LIMK1 P53667 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL995934 0.93 MTOR (0.68) MTORPIK3CAPIK3CDPIK3CGPIK3CB
Dactolisib SCHEMBL30186162 0.88 MTOR (1.00) MTORPIK3CAPIK3CDPIK3CGPIK3CB
Dactolisib SCHEMBL143623 0.88 MTOR (1.00) MTORPIK3CAPIK3CDPIK3CGPIK3CB
Dactolisib SCHEMBL29370906 0.88 MTOR (1.00) MTORPIK3CAPIK3CDPIK3CGPIK3CB
Dactolisib SCHEMBL2424463 0.88 MTOR (1.00) MTORPIK3CAPIK3CDPIK3CGPIK3CB
SCHEMBL993965 0.84 PIK3CA (0.55) MTORPIK3CAPIK3CDPIK3CGPIK3CB
Dactolisib SCHEMBL995465 0.83 MTOR (0.83) MTORPIK3CAPIK3CDPIK3CGPIK3CB
Dactolisib SCHEMBL30587353 0.83 MTOR (0.83) MTORPIK3CAPIK3CDPIK3CGPIK3CB
SCHEMBL15747813 0.83 MTOR (0.89) MTORPIK3CAPIK3CDPIK3CGPIK3CB
SCHEMBL22616736 0.82 MTOR (0.77) MTORPIK3CAPIK3CDPIK3CGPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2270008-B1 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors NOVARTIS AG (CH) 2012-10-03 — — EP claimed
US-7994170-B2 1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors NOVARTIS AG (CH) 2011-08-09 — — US claimed
EP-2292617-A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors Novartis AG (CH) 2011-03-09 — — EP claimed
EP-2270008-A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors Novartis AG (CH) 2011-01-05 — — EP claimed
US-20100056558-A1 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-04 — — US claimed
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors NOVARTIS AG (CH) 2008-08-14 — — US claimed
US-9370508-B2 Imidazoquinolines as dual lipid kinase and mTOR inhibitors NOVARTIS AG (CH) 2016-06-21 — — US disclosed
EP-2624831-A1 PHARMACEUTICAL COMBINATIONS Novartis AG (CH) 2013-08-14 — — EP disclosed
US-20130178479-A1 PHARMACEUTICAL COMBINATIONS NOVARTIS AG (CH) 2013-07-11 — — US disclosed
US-8431592-B2 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors NOVARTIS AG (CH) 2013-04-30 — — US disclosed
US-20120282252-A1 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes NOVARTIS AG (CH) 2012-11-08 — — US disclosed
EP-2270008-B1 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors NOVARTIS AG (CH) 2012-10-03 — — EP disclosed
US-20120207751-A1 Imidazoquinolines as lipid kinase inhibitors NOVARTIS AG (CH) 2012-08-16 — — US disclosed
US-20100056558-A1 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-04 — — US disclosed
US-7667039-B2 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors NOVARTIS AG (CH) 2010-02-23 — — US disclosed
EP-2129379-A1 IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS Novartis AG (CH) 2009-12-09 — — EP disclosed
WO-2008103636-A1 IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS NOVARTIS AG (CH) 2008-08-28 — — WO disclosed
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors NOVARTIS AG (CH) 2008-08-14 — — US disclosed
EP-1888578-A2 IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2008-02-20 — — EP disclosed
WO-2006122806-A2 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2006-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056558-A1 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS PDPK1, PI4KA, PIP4K2A MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885
US-20120207751-A1 Imidazoquinolines as lipid kinase inhibitors PI4KA, PDPK1, PI4KB MTOR 171/4885PIK3CA 29/4885PIK3CD 58/4885
US-20130178479-A1 PHARMACEUTICAL COMBINATIONS MTOR, RICTOR, PIK3CA MTOR 1/4885PIK3CA 3/4885PIK3CD 4/4885
US-20120282252-A1 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes KDR, FLT4, TEK MTOR 2286/4885PIK3CA 1091/4885PIK3CD 1413/4885
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors PDPK1, PI4KA, PIP4K2A MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.